​​​​McKesson Compile announces data products crafted for the oncology market​

IRVING, Texas, March 26, 2025 — McKesson Compile™, a leading provider of analytics-ready data products and tailored intelligence to life science companies, today announced a focus ​ in new oncology-specific enhancements to its Provider 360 ReadyData™ offering.  These updates include the utilization of McKesson oncology data in the development of their data products to drive increased coverage and accuracy.​ 

“As new cancer treatments become more targeted, it becomes more difficult for biopharma companies to identify the doctors and patients they need to reach to market their therapies,” said Olivia vonNieda, Vice President and General Manager, McKesson Compile. “By leveraging our proprietary oncology data, analytics, and expertise, biopharma companies can remove blind spots in their understanding of the market.” 

Provider 360 ReadyData, McKesson Compile’s provider reference and affiliations dataset, includes information on U.S. providers, organizations, and their corresponding affiliations. Its unique, proprietary affiliations scoring provides teams with better insight into the complex care team relationships, and flexible hierarchies allow for better cross-system integration. McKesson Compile utilizes a tech-forward, automated sourcing process and updates data on a monthly basis for enhanced accuracy and recency.  

Provider 360 ReadyData has especially high coverage rates for oncology providers and their affiliations to the organizations treating oncology patients, with near 100 percent coverage of oncology MDs and with 94 percent of those having accurate affiliations information captured in the dataset. New enhancements crafted specifically for oncology use cases will provide important data elements including oncology specialty and sub-specialty classifications, improvement in fidelity and accuracy of GPO affiliations, and indication of organizational infusion capabilities. 

“An estimated two million people were diagnosed with cancer in 2024, highlighting the tremendous need for patient access to potentially transformative treatments,” said Kirby Forlin, Senior Vice President, Data Commercialization & Advanced Analytics, McKesson. “The opportunity to make a difference within oncology is huge. By leveraging McKesson’s wealth of oncology data, we are helping to bridge the knowledge gaps that exist around where patients receive care and who their care teams are. Ultimately, we want to enable oncology brands to improve patient lives by getting their therapies to the patients that need them.” 

To learn more about Provider 360 ReadyData, visit mckessoncompile.com/provider-360. 

About McKesson Compile 

McKesson Compile helps life sciences companies develop and commercialize life-saving innovations by providing analytics-ready healthcare data products and tailored intelligence. We offer extensive in-house life science expertise and enable customers to move faster and remove friction through premium customer service. For more information on how to optimize your strategy with the right data, visit mckessoncompile.com.  

About McKesson Corporation 

McKesson Corporation is a diversified healthcare services leader dedicated to advancing health outcomes for patients everywhere. Our teams partner with biopharma companies, care providers, pharmacies, manufacturers, governments, and others to deliver insights, products, and services to help make quality care more accessible and affordable. Learn more about how McKesson is impacting virtually every aspect of healthcare at McKesson.com and read Our Stories.